7 References

1. Ansell D, Feest T. 2nd Annual Report of the UK Renal Registry, 1999.

2. Provision of Services for Adult Patients with Renal Disease in the United Kingdom.
Royal College of Physicians of London and the Renal Association. London, 1991.

3. Roderick PJ, Ferris G, Feest TG. The Provision of Renal Replacement Therapy for Adults in England
and Wales: recent trends and future directions. QJM, 1998, 91 (8): 581-7.

4. Eardley I, Davey IP, Smith S. Four years experience of regional audit in the Midlands: Rapid changes in practice patterns and outcomes.The Renal Association; September 2000; St John's College, Cambridge.

5. United Kingdom Transplant Support Service Authority (UKTSSA). Transplant Activity 1998. Bristol, 1999.

6. Purchasing renal services. EL(96)35. London: Department of Health, 1996.

7. Davies R, Roderick P. Predicting the future demand for renal replacement therapy in England using simulation modelling. Nephrol Dial Transplant 1997;12(12):2512-6.

8. Wight J, Olliver A, Payne N. A computer model for predicting the demand for end-stage renal failure (ESRF) treatment, contract setting and monitoring. Nephrol Dial Transplant 1996;11(7):1286-91.

9. Renal Services Review. Northern Region, NHS Executive July 1999.

10. Renal Replacement Therapy - A Strategic Framework for the Eastern Region, RSSCG Renal Review Group, NHS Executive, 2000.

11. Valderrabano F, Berthoux FC, Jones EH, Mehls O. Report on management of renal failure in Europe, XXV, 1994 end stage renal disease and dialysis report. The EDTA-ERA Registry. European Dialysis and Transplant Association-European Renal Association. Nephrol Dial Transplant 1996;11 Suppl 1:2-21.

12. United States Renal Data System (USRDS). USRDS 1999 Annual Data Report. Bethesda: Department of Health and Human Services, Public Health Service, National Institutes of Health. Division of Kidney, Urologic and Hematologic Diseases of the National Institiute of Diabetes and Digestive and Kidney Diseases, 1999.

13. Roderick PJ, Raleigh VS, Hallam L, Mallick NP. The need and demand for renal replacement therapy in ethnic minorities in England. J Epidemiol Community Health 1996;50(3):334-9.

14. Roderick PJ, Jones I, Raleigh VS, McGeown M, Mallick N. Population need for renal replacement therapy in Thames regions: ethnic dimension. Brit Med J 1994;309(6962):1111-4.

15. Roderick P, Clements S, Diamond, Storkey M, Raleigh VS. Estimating demand for renal replacement therapy in Greater London:the impact of demographic trends in ethnic minority populations. Health Trends 1998;30(2):46-50.

16. Raleigh VS. Diabetes and hypertension in Britain's ethnic minorities: implications for the future of renal services. Brit Med J 1997;314(7075):209-13.

17. Jones NF, Goodwin FJ, Roberts AP. Manpower and workload in adult renal medicine in the United Kingdom 1975-82. Br Med J (Clin Res Ed) 1984;288(6422):992-4.

18. Dalziel M, Garrett C. Intraregional variation in treatment of end stage renal failure. Br Med J (Clin Res Ed) 1987;294(6584):1382-3.

19. Roderick P, Clements S, Stone N, Martin D, Diamond I. What determines geographical variation in rates of acceptance onto renal replacement therapy in England? J Health Serv Res Policy 1999;4(3):139-46.

20. Department of Health. Report of an independent review of specialist services in London.
London: HMSO, 1993.

21. Department of Health. Renal Purchasing Guidelines. London: NHS Executive, London, 1996.

22. Held PJ, Levin NW, Bovbjerg RR, Pauly MV, Diamond LH. Mortality and duration of hemodialysis treatment. JAMA 1991;265(7):871-5.

23. Acchiardo SR, Hatten KW, Ruvinsky MJ, Dyson B, Fuller J, Moore LW. Inadequate dialysis increases gross mortality rate. ASAIO J 1992;38(3):M282-5.

24. The Renal Association. Treatment of adult patients with renal failure. Recommended standards and audit measures. First edition. London: Royal College of Physicians, 1995.

25. The Renal Association. Treatment of adult patients with renal failure. Recommended standards and audit measures. Second edition. London: Renal Association and Royal College of Physicians, 1997.

26. Department of Health. Working together: securing a quality workforce for the NHS, 1998.

27. Department of Health NHS Executive. Information for health an information strategy for the modern NHS 1998-2005 a national strategy for local implementation. London, 1998.

28. The National Plan for the NHS, HMSO, July 2000.

29. Department of Health. The NHS performance assessment framework, 1999.

30. Chandna SM, Schulz J, Lawrence C, Greenwood RN, Farrington K. Is there a rationale for rationing chronic dialysis? A hospital based cohort study of factors affecting survival and morbidity. Brit Med J 1999;318(7178):217-23.

31. Krolewski AS, Warram JH, Christlieb AR, Busick EJ, Kahn CR. The changing natural history of nephropathy in type I diabetes. Am J Med 1985;78(5):785-94.

32. American Diabetes Association. Diabetic Nephropathy. Diabetes Care 2000;23(Suppl 1, January 2000).

33. Cowie CC, Port FK, Wolfe RA, Savage PJ, Moll PP, Hawthorne VM. Disparities in incidence of diabetic end-stage renal disease according to race and type of diabetes. N Engl J Med 1989;321(16):1074-9.

34. Simmons D, Williams DR, Powell MJ. Prevalence of diabetes in different regional and religious south Asian communities in Coventry. Diabet Med 1992;9(5):428-31.

35. Allawi J, Rao PV, Gilbert R, Scott G, Jarrett RJ, Keen H, et al. Microalbuminuria in non-insulin-dependent diabetes: its prevalence in Indian compared with Europid patients. Br Med J (Clin Res Ed) 1988;296(6620):462-4.

36. Moloney A, Tunbridge WM, Ireland JT, Watkins PJ. Mortality from diabetic nephropathy in the United Kingdom. Diabetologia 1983;25(1):26-30.

37. Most RS, Sinnock P. The epidemiology of lower extremity amputations in diabetic individuals. Diabetes Care 1983;6(1):87-91.

38. Trautner C, Haastert B, Giani G, Berger M. Incidence of lower limb amputations and diabetes. Diabetes Care 1996;19(9):1006-9.

39. van Houtum WH, Lavery LA, Harkless LB. The impact of diabetes-related lower-extremity amputations in The Netherlands. J Diabetes Complications 1996;10(6):325-30.

40. Madhavan S, Stockwell D, Cohen H, Alderman MH. Renal function during
antihypertensive treatment. Lancet 1995;345(8952):749-51.

41. Buck K, Feehally J. Diabetes and renal failure in Indo-Asians in the UK--a paradigm for the study of disease susceptibility [editorial]. Nephrol Dial Transplant 1997;12(8):1555-7.

42. Navis G, de Zeeuw D, de Jong PE. ACE-inhibitors: panacea for progressive renal disease. Lancet 1997;349(9069):1852-3

43. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995;123(10):754-62.

44. Williams PS, Fass G, Bone JM. Renal pathology and proteinuria determine progression in untreated mild/moderate chronic renal failure. Q J Med 1988;67(252):343-54.

45. Locatelli F, Marcelli D, Comelli M, Alberti D, Graziani G, Buccianti G, et al. Proteinuria and blood pressure as causal components of progression to end-stage renal failure. Northern Italian Cooperative Study Group. Nephrol Dial Transplant 1996;11(3):461-7.

46. Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH. The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis. Ann Intern Med 1996;124(7):627-32.

47. Giatras I, Lau J, Levey AS. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group. Ann Intern Med 1997;127(5):337-45.

48. Kasiske BL, Kalil RS, Ma JZ, Liao M, Keane WF. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993;118(2):129-38.

49. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 1998;352(9136):1252-6.

50. Gilbert RE, Tsalamandris C, Bach LA, Panagiotopoulos S, O'Brien RC, Allen TJ, et al. Long-term glycemic control and the rate of progression of early diabetic kidney disease. Kidney Int 1993;44(4):855-9.

51. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329(14):977-86.

52. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352(9131):837-53.

53. Parving HH. Antihypertensive drugs and diabetes mellitus. Dan Med Bull 1987;34 Suppl 1:16-7.

54. Marre M, Chatellier G, Leblanc H, Guyene TT, Menard J, Passa P. Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria. Brit Med J 1988;297(6656):1092-5.

55. Mathiesen ER, Hommel E, Giese J, Parving HH. Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria.
Brit Med J 1991;303(6794):81-7.

56. Lovell H. Angiotensin converting enzyme inhibitors in normotensive diabetic patients with microalbuminuria (Cochrane Review). Issue 4;2000 (Oxford: Update Software.).

57. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group N Engl J Med 1993;329(20):1456-62.

58. Raine AE, Margreiter R, Brunner FP, Ehrich JH, Geerlings W, Landais P, et al. Report on management of renal failure in Europe, XXII, 1991. Nephrol Dial Transplant 1992;7 Suppl 2:7-35.

59. Orth SR, Ritz E, Schrier RW. The renal risks of smoking. Kidney Int 1997;51(6):1669-77.

60. Orth SR, Stockmann A, Conradt C, Ritz E, Ferro M, Kreusser W, et al. Smoking as a risk factor for end-stage renal failure in men with primary renal disease. Kidney Int 1998;54(3):926-31.

61. Attman PO. Progression of renal failure and lipids-is there evidence for a link in humans? [editorial]. Nephrol Dial Transplant 1998;13(3):545-7.

62. Samuelsson O, Mulec H, Knight-Gibson C, Attman PO, Kron B, Larsson R, et al. Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency.
Nephrol Dial Transplant 1997;12(9):1908-15.

63. National service framework for coronary heart disease; emerging findings. London:
Department of Health, 1998.

64. Eadington DW. Delayed referral for dialysis [editorial]. Nephrol Dial Transplant 1996;11(11):2124-6.

65. Lameire N, Van Biesen W. The pattern of referral of patients with end-stage renal disease to the nephrologist--a European survey. Nephrol Dial Transplant 1999;14 Suppl 6:16-23.

66. Khan IH, Catto GR, Edward N, MacLeod AM. Chronic renal failure: factors influencing nephrology referral. QJM 1994;87(9):559-64.

67. Mendelssohn DC, Kua BT, Singer PA. Referral for dialysis in Ontario.
Arch Intern Med 1995;155(22):2473-8.

68. Innes A, Rowe PA, Burden RP, Morgan AG. Early deaths on renal replacement therapy: the need for early nephrological referral. Nephrol Dial Transplant 1992;7(6):467-71.

69. Report of the Working Party to Review Organ Transplantation: The Royal College of Surgeons
of England, 1999.

70. The Review of the United Kingdom Transplant Support Service Authority (UKTSSA) 1998/99. London: Department of Health, 2000.

71. Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities.
Am J Kidney Dis 1990;15(5):458-82.

72. The US Recombinant Human Erythropoietin Predialysis Study Group. Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients. Am J Kidney Dis 1991; 18: 50-59.

73. Portoles J, Torralbo A, Martin P, Rodrigo J. Herrero JA, Barrientos A. Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis 1997; 29: 541-548

74. Hayashi T, Suzuki A, Shoji T, Togawa M, Okada N, Tsubakihara Y, Imai E, Hori M. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis 2000; 35: 250-256.

75. Cost and outcome implications of the Organisation of Vascular Services. NCC Health Technology Assessment; Vol 4, No 22, 2000.

76. Young EW, Goodkin DA, Mapes DL, Port FK, Keen ML, Chenk, Maroni BL, Wolfe RA, Held PJ.
The dialysis outcomes and practise patterns study (DOPPS): An international haemodialysis study. Kidney International, Vol 57, Suppl. 74 (2000), pp S-74 - S-82.

77. Pisoni RL, Young EW, Greenwood RN, Hecking E, Goodkin DA, Wolfe RA, Held PJ. Comparison of vascular access use in the US and Europe: The Dialysis Outcomes and Practice Patterns Study (DOPPS). American Society of Nephrology, Toronto, 2000.

78. Smith SA. A step towards effective self regulation. Brit Med J 1999;318(7189):1017.

79. Gudex CM. Health-related quality of life in endstage renal failure. Qual Life Res 1995;4(4):359-66.

80. Rittman M, Northsea C, Hausauer H, Green C, Swenson L . Living with renal failure. American Nephrology Nurses Association Journal 1993; 20: 327-31.

81. Young EW, Oszol SM, Bommer J, Canaud BJ, Port FK, Held PJ. Risk of Hospitalisation and length of stay among haemodialysis patients in the US and Europe. American Society of Nephrology, Toronto, 2000.

82. Farrell M, Almond M. Standard documentation for holiday dialysis. British Journal of Renal Medicine. Summer 2000.

83. Port FK, Wolfe RA, Hawthorne VM, Ferguson CW. Discontinuation of dialysis therapy as a cause of death. Am J Nephrol 1989;9(2):145-9.

84. Mailloux LU, Bellucci AG, Wilkes BM, Napolitano B, Mossey RT, Lesser M, et al. Mortality in dialysis patients: analysis of the causes of death. Am J Kidney Dis 1991;18(3):326-35.

85. A Health Service for all the talents. NHS Executive, April 2000.

86. Nurses and Technicians in high technology areas. IMP Report 239, 1992.

87. Scottish Office. Acute Service Review Report. Edinburgh:Stationery Office, 1998.